UPDATE 1-Actelion's heart-lung drug meets main goal in late-stage study

June 16, 2014 5:12 AM

3 0

ZURICH, June 16 (Reuters) - Actelion Ltd said its experimental heart and lung drug Selexipag met its primary goal in a late-stage study, giving the Swiss biotech company a potential second big seller to replenish its product pipeline.

Results of the Phase III study involving 1,156 patients found that Selexipag reduced the risk of a morbidity/mortality event by 39 percent versus a placebo in patients suffering from pulmonary arterial hypertension (PAH).

Read more

To category page